Cardlytics 8-K: Officer/Director Changes, Comp Arrangements
Ticker: CDLX · Form: 8-K · Filed: Jan 2, 2024 · CIK: 1666071
| Field | Detail |
|---|---|
| Company | Cardlytics, Inc. (CDLX) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $30,000, $20,000, $165,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-change, compensation, corporate-governance
TL;DR
**Cardlytics filed an 8-K on Dec 29, 2023, signaling executive changes and compensation updates.**
AI Summary
Cardlytics, Inc. filed an 8-K on January 2, 2024, reporting an event that occurred on December 29, 2023. This filing indicates a change related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' and 'Regulation FD Disclosure'. While the specific details of the personnel changes or compensatory arrangements are not provided in this summary, investors should note that changes in leadership or executive compensation can signal shifts in company strategy or financial health, potentially impacting the stock's future performance.
Why It Matters
Changes in executive leadership or compensation can signal strategic shifts or financial health concerns, directly influencing investor confidence and the company's future direction.
Risk Assessment
Risk Level: medium — The filing indicates changes in officers/directors and compensatory arrangements, which can introduce uncertainty regarding future company direction and stability.
Analyst Insight
Investors should monitor subsequent filings or company announcements for specific details regarding the personnel changes and compensatory arrangements mentioned, as these will provide clarity on potential strategic shifts or financial implications.
Key Players & Entities
- Cardlytics, Inc. (company) — the registrant filing the 8-K
- December 29, 2023 (date) — date of the earliest event reported
- January 2, 2024 (date) — date the 8-K was filed
- 001-38386 (other) — Commission File Number
- CDLX (other) — Trading symbol for Common Stock
- The Nasdaq Stock Market LLC (other) — exchange where Common Stock is registered
FAQ
What specific items did Cardlytics, Inc. report in this 8-K filing?
Cardlytics, Inc. reported under Item 5.02, 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers,' and Item 7.01, 'Regulation FD Disclosure,' as well as Item 9.01, 'Financial Statements and Exhibits.'
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on December 29, 2023.
What is the trading symbol and exchange for Cardlytics, Inc.'s Common Stock?
The trading symbol for Cardlytics, Inc.'s Common Stock is CDLX, and it is registered on The Nasdaq Stock Market LLC.
What is Cardlytics, Inc.'s state of incorporation and IRS Employer Identification Number?
Cardlytics, Inc. is incorporated in Delaware and has an I.R.S. Employer Identification No. of 26-3039436.
What is the business address and phone number of Cardlytics, Inc. as listed in the filing?
The business address of Cardlytics, Inc. is 675 Ponce de Leon Avenue NE, Suite 4100, Atlanta, Georgia 30308, and their business phone number is (888) 798-5802.
Filing Stats: 1,705 words · 7 min read · ~6 pages · Grade level 10.2 · Accepted 2024-01-02 16:06:48
Key Financial Figures
- $30,000 — titled to receive an annual retainer of $30,000 for his service as director and an addi
- $20,000 — or and an additional annual retainer of $20,000 for his service as a member of the Audi
- $165,000 — t award with a grant date fair value of $165,000, not to exceed 11,000 shares of common
Filing Documents
- cdlx-20231229.htm (8-K) — 41KB
- cdlx_exx991x122023xboardan.htm (EX-99.1) — 9KB
- cdlx-20231229_g1.jpg (GRAPHIC) — 26KB
- 0001666071-24-000006.txt ( ) — 270KB
- cdlx-20231229.xsd (EX-101.SCH) — 3KB
- cdlx-20231229_def.xml (EX-101.DEF) — 14KB
- cdlx-20231229_lab.xml (EX-101.LAB) — 28KB
- cdlx-20231229_pre.xml (EX-101.PRE) — 15KB
- cdlx-20231229_htm.xml (XML) — 3KB
01 REGULATION FD DISCLOSURE
ITEM 7.01 REGULATION FD DISCLOSURE On January 2, 2024, the Company issued a press release announcing the appointment of Mr. Fernandez and Mr. Francis to the Board of Directors and the resignation of Mr. Balen and Mr. Adams from the Board. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report. The information contained in the press release furnished as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.
01 FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS (d) Exhibits Exhibit Exhibit Description 99.1 Press release dated January 2, 2024
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Cardlytics, Inc. Date: January 2, 2024 By: /s/ Alexis DeSieno Alexis DeSieno Chief Financial Officer (Principal Financial and Accounting Officer)